InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, is pleased to announce the strengthening of its R&D Team with Grégoire Prevost, PhD as Chief Development Officer and Paula van Noort, PhD as Project Manager R&D.
Gregoire joined InteRNA in March of this year as member of the Management Team of the Company to manage and further develop the R&D programs towards the clinic. Grégoire brings 20+ years of translational oncology research to the Company. Prior to InteRNA, Grégoire served as the Director Oncology Translational Research & Member Oncology Portfolio MT at IPSEN, a France-based, Euronext-listed biopharmaceutical company.
Paula joined InteRNA in November of 2010 to manage the R&D projects in collaboration with our academic partners. Paula brings ample experience and knowledge in lead finding and optimization to the Company. Prior to InteRNA, Paula served as team leader at Organon/Schering-Plough/Merck responsible for drug discovery ranging from target validation to selection of lead compounds in the field of contraception, fertility and hormone dependent cancers.